Log in

NASDAQ:APOP - CELLECT BIOTECH/S Stock Price, Forecast & News

$2.65
+0.03 (+1.15 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$2.52
Now: $2.65
$2.78
50-Day Range
$0.40
MA: $2.36
$3.10
52-Week Range
$1.58
Now: $2.65
$19.15
Volume50,947 shs
Average Volume100,459 shs
Market Capitalization$5.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.82
Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APOP
CUSIPN/A
Phone972-9974-1444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.85 per share

Profitability

Net Income$-5,370,000.00

Miscellaneous

Employees28
Market Cap$5.94 million
Next Earnings Date3/16/2020 (Estimated)
OptionableNot Optionable

Receive APOP News and Ratings via Email

Sign-up to receive the latest news and ratings for APOP and its competitors with MarketBeat's FREE daily newsletter.


CELLECT BIOTECH/S (NASDAQ:APOP) Frequently Asked Questions

What is CELLECT BIOTECH/S's stock symbol?

CELLECT BIOTECH/S trades on the NASDAQ under the ticker symbol "APOP."

How were CELLECT BIOTECH/S's earnings last quarter?

CELLECT BIOTECH/S (NASDAQ:APOP) posted its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.01. View CELLECT BIOTECH/S's Earnings History.

When is CELLECT BIOTECH/S's next earnings date?

CELLECT BIOTECH/S is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for CELLECT BIOTECH/S.

What price target have analysts set for APOP?

1 brokerages have issued 1-year price targets for CELLECT BIOTECH/S's stock. Their forecasts range from $12.00 to $12.00. On average, they expect CELLECT BIOTECH/S's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 352.8% from the stock's current price. View Analyst Price Targets for CELLECT BIOTECH/S.

What is the consensus analysts' recommendation for CELLECT BIOTECH/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELLECT BIOTECH/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CELLECT BIOTECH/S.

Has CELLECT BIOTECH/S been receiving favorable news coverage?

Press coverage about APOP stock has trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CELLECT BIOTECH/S earned a news impact score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for CELLECT BIOTECH/S.

Who are some of CELLECT BIOTECH/S's key competitors?

What other stocks do shareholders of CELLECT BIOTECH/S own?

Who are CELLECT BIOTECH/S's key executives?

CELLECT BIOTECH/S's management team includes the folowing people:
  • Mr. Kasbian Nuriel Chirich, Co-Founder & Exec. Chairman (Age 61)
  • Dr. Shai Yarkoni, Co-Founder, CEO & Director (Age 61)
  • Mr. Eyal Leibovitz, Chief Financial Officer (Age 58)
  • Dr. Ronit Bakimer-Kleiner, Chief Devel. Officer (Age 57)
  • Dr. Amos Ofer, VP of Operations (Age 43)

Who are CELLECT BIOTECH/S's major shareholders?

CELLECT BIOTECH/S's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (1.48%).

Which major investors are buying CELLECT BIOTECH/S stock?

APOP stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

How do I buy shares of CELLECT BIOTECH/S?

Shares of APOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CELLECT BIOTECH/S's stock price today?

One share of APOP stock can currently be purchased for approximately $2.65.

How big of a company is CELLECT BIOTECH/S?

CELLECT BIOTECH/S has a market capitalization of $5.94 million. CELLECT BIOTECH/S employs 28 workers across the globe.View Additional Information About CELLECT BIOTECH/S.

What is CELLECT BIOTECH/S's official website?

The official website for CELLECT BIOTECH/S is http://www.cellect.co/.

How can I contact CELLECT BIOTECH/S?

CELLECT BIOTECH/S's mailing address is 23 Hata'as Street, Kfar Saba L3, 44425. The company can be reached via phone at 972-9974-1444 or via email at [email protected]


MarketBeat Community Rating for CELLECT BIOTECH/S (NASDAQ APOP)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  327 (Vote Outperform)
Underperform Votes:  242 (Vote Underperform)
Total Votes:  569
MarketBeat's community ratings are surveys of what our community members think about CELLECT BIOTECH/S and other stocks. Vote "Outperform" if you believe APOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel